UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37983 TechnipFMC plc (Exact name of registrant as specified in its charter) United Kingdom 98-1283037 (State or other jurisdiction of incorporat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 Commission File Number 1-11758 (Exact name of Registrant as specified in its charter) | Delaware 1585 Broadway | | 36-3145972 | (212) 761-4000 | | --- | --- | --- | --- | | (State or other jurisdiction of | New York, NY 10036 | (I.R.S. Employer Identification No.) | (Registrant's telephone ...

Exhibit 99.1 FOR IMMEDIATE RELEASE 4714 Gettysburg Road Mechanicsburg, PA 17055 NYSE Symbol: SEM Select Medical Holdings Corporation Announces Results For Its Fourth Quarter and Year Ended December 31, 2025, Its 2026 Business Outlook, and Cash Dividend MECHANICSBURG, PENNSYLVANIA — February 19, 2026 — Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its fourth quarter and year ended December 31, 2025, its 2026 business outlook, and the decl ...

Media Relations Consolidated Edison, Inc. New York, NY 10003 www.conEdison.com Exhibit 99.1 212 460 4111 (24 hours) 4 Irving Place FOR IMMEDIATE RELEASE Contact: Allan Drury February 19, 2026 212-460-4111 CON EDISON REPORTS 2025 EARNINGS NEW YORK - Consolidated Edison, Inc. (Con Edison) (NYSE: ED) today reported 2025 net income for common stock of $2,023 million or $5.66 a share compared with $1,820 million or $5.26 a share in 2024. Adjusted earnings (non- GAAP) were $2,038 million or $5.70 a share in 2025 ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or | | | For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0022692 (State or Other Jurisdiction of Incorporat ...

Financial Performance - Q4 2025 Net Sales were $1.3 billion, down 2% year-over-year, primarily due to a 4% decrease in volume, partially offset by a 1% price increase and a 1% currency tailwind [7]. - Q4 2025 Net Loss attributable to Chemours was $47 million, or $0.31 per diluted share, compared to a Net Loss of $11 million, or $0.08 per diluted share in Q4 2024 [8]. - Adjusted EBITDA for Q4 2025 was $128 million, down 24% from $168 million in the prior-year quarter, driven by higher costs impacting net loss [8]. - Full year 2025 Net Sales were $5.8 billion, flat compared to the prior year, with TSS reporting record annual sales driven by higher volume and price [9]. - Full year 2025 Net Loss attributable to Chemours was $386 million, or $2.57 per diluted share, compared to Net Income of $69 million, or $0.46 per diluted share in the prior year [10]. - Adjusted EBITDA for the full year 2025 was $742 million, down from $768 million in the prior year, primarily due to lower pricing and cost absorption issues [10]. Segment Performance - TSS segment Q4 2025 Net Sales were $444 million, a 14% increase year-over-year, driven by a 10% price increase and a 3% volume increase [12]. - TiO2 segment Q4 2025 Net Sales were $561 million, an 11% decrease year-over-year, primarily due to a 6% decrease in price globally [17]. - APM segment Q4 2025 Net Sales were $312 million, a 4% decrease year-over-year, primarily driven by an 8% decrease in volume [21]. - APM segment Q4 2025 Adjusted EBITDA decreased 74% to $12 million, primarily due to a non-cash inventory charge and a less favorable product mix [23]. - APM segment full year 2025 Net Sales were $1.3 billion, a 5% decrease compared to full year 2024, primarily due to weaker global demand [25]. - Adjusted EBITDA for APM decreased 32% from the prior year to $108 million, driven by lower cost absorption and operational disruptions [25]. - Other Non-Reportable Segment had Net Sales of $50 million and Adjusted EBITDA of $8 million for the full year 2025 [26]. Cash Flow and Debt - Free Cash Flows for Q4 2025 were $92 million, reflecting a Free Cash Flow Conversion of 72%, compared to $29 million or 17% in Q4 2024 [30]. - As of December 31, 2025, consolidated gross debt was $4.2 billion, with a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis [28]. - Cash provided by operating activities was $264 million for the year ended December 31, 2025, a significant improvement from cash used of $633 million in 2024 [51]. - Cash used for investing activities was $206 million for the year ended December 31, 2025, compared to $353 million in 2024 [51]. - The company issued $748 million in new debt during the year ended December 31, 2025, compared to $606 million in 2024 [51]. Future Outlook - The Company anticipates consolidated Net Sales to increase by 3 to 5% in Q1 2026, with Adjusted EBITDA expected to range between $120 million and $150 million [31]. - The Company expects 2026 Net Sales growth in the range of 3 to 5% and Adjusted EBITDA of $800 million to $900 million [37]. - Capital expenditures for 2026 are anticipated to range from $275 million to $325 million, with Free Cash Flow Conversion above 25% [37]. - Estimated Free Cash Flows for the year ending December 31, 2026, are projected to be between $200 million and $270 million [67]. - Estimated Adjusted EBITDA for the year ending December 31, 2026, is expected to range from $800 million to $900 million [68]. - Net income attributable to Chemours for the year ending December 31, 2026, is estimated to be between $165 million and $225 million [68]. - Adjusted Net Income for the year ending December 31, 2026, is projected to be between $130 million and $180 million [68]. Legal and Environmental Charges - The company incurred restructuring and asset-related charges of $58 million for the year ended December 31, 2025, primarily related to the exit of the SPS Capstone™ business [59]. - Litigation-related charges for the year ended December 31, 2025, amounted to $320 million, significantly impacting the financial results due to various legal settlements [59]. - Environmental charges for the year ended December 31, 2025, included $93 million related to remediation expenses, reflecting ongoing liabilities [59]. Shareholder Information - Basic loss per share for the year ended December 31, 2025, was $(2.57), while adjusted diluted earnings per share were $0.95, down from $1.20 in 2024 [62]. - The weighted-average number of common shares outstanding for the year ended December 31, 2025, was approximately 150.8 million [62].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 1-32740 ENERGY TRANSFER LP (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ...

Exhibit 99.1 NEWS RELEASE FINANCIAL NEWS BRIEF February 19, 2026 For Immediate Release Vicor Corporation Reports Results for the Fourth Quarter and Year Ended December 31, 2025 Andover, Mass., February 19, 2026 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: VICR) today reported financial results for the fourth quarter and year ended December 31, 2025. These results will be discussed later today at 5:00 p.m. Eastern Time, during management's quarterly investor conference call. The details for the call are bel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________________________ FORM 10-K __________________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39653 ___________________________ BLUE OWL CAPITAL INC. (Exact name of regis ...